1. Vascular endothelial growth factor expression in malignant melanoma: prognostic versus diagnostic usefulness.
- Author
-
Bayer-Garner IB, Hough AJ Jr, and Smoller BR
- Subjects
- Diagnosis, Differential, Female, Humans, Immunohistochemistry, Male, Melanoma diagnosis, Middle Aged, Nevus diagnosis, Predictive Value of Tests, Prognosis, Skin Neoplasms diagnosis, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factors, Endothelial Growth Factors biosynthesis, Lymphokines biosynthesis, Melanoma metabolism, Nevus metabolism, Skin Neoplasms metabolism
- Abstract
Vascular endothelial growth factor (VEGF), an endothelial cell mitogen, plays a role in angiogenesis and progression in malignant melanoma. VEGF expression was examined in 62 biopsy specimens of melanocytic proliferations, including 45 malignant melanomas, 3 cellular blue nevi, 12 atypical compound nevi, and 2 Spitz nevi. The cases of malignant melanoma included 11 in situ melanomas, 18 Clark Level II, 9 Clark Level III, and 7 Clark Level IV tissue samples. All of the specimens were fixed in formalin and embedded in paraffin. Cytoplasmic immunoreactivity for VEGF was demonstrated in 19 (42%) of 45 melanoma samples, but there was no immunoreactivity for VEGF exhibited by any of the atypical compound melanocytic nevi, cellular blue nevi, or Spitz nevi (P < .009). Immunoreactivity for VEGF was found to be related to tumor thickness (as evidenced by Clark level [P < .03]) and to absence of regression (P < .04). Although VEGF is not a useful prognostic indicator for malignant melanoma, it may be useful as a discriminating factor between malignant melanoma and benign melanocytic lesions, and it may offer some insight into tumor growth.
- Published
- 1999